Skip to content

Study · Non-randomized trial · n = 42 · 1988

2 results

Neurogenic claudication and root claudication treated with calcitonin. A double-blind trial.

Porter RW, Miller CG

Spine1 Sept 1988Cited by 28 (Europe PMC)

PMID2974630 (opens in a new tab)DOI10.1097/00007632-198809000-00015 (opens in a new tab)PepBankPUB-02974630
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with claudication, 5 of 20 salmon calcitonin recipients and one of 22 placebo recipients responded, without a significant difference.

    In plain wordsIn patients with claudication, response proportions did not differ significantly between salmon calcitonin and placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeResponder proportion
    Study

    n = 42

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    100 IU four times a week · 8 weeksAs given in this study (human).

    Measurements

    Responders
    5 patients
    salmon calcitonin
    Treated
    20 patients
    salmon calcitonin
    Responders
    1 patients
    placebo
    Treated
    22 patients
    placebo

    Source sentences

    Summary
    Five of 20 SCT and one of 22 placebo patients were classified as responders.
    2 context sentences
    Summary · context
    There was no statistically significant difference between the treatment groups in the proportion of responders.
    Summary · context
    Forty-two patients with either neurogenic claudication or unilateral root claudication were analyzed in a double-blind comparison of salmon calcitonin (SCT) and placebo, receiving either 100 IU SCT or 1 ml saline four times a week for 8 weeks.
  2. 02HumanNon-randomized trialEfficacy outcome

    In former placebo recipients with claudication, seven of eighteen improved walking distance after salmon calcitonin, but an organic response was not established.

    In plain wordsIn former placebo recipients with claudication, salmon calcitonin preceded walking improvement, but an organic response was not established.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseWalking distance improvement after placebo
    Study

    n = 18

    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Improved walking distance
    7 patients
    placebo group later given salmon calcitonin
    Patients
    18 patients
    placebo group later given salmon calcitonin

    Source sentences

    Summary
    Seven of eighteen of the placebo group who later received salmon calcitonin improved their walking distance.
    2 context sentences
    Summary · context
    The authors have not established that this is an organic response.
    Summary · context
    Forty-two patients with either neurogenic claudication or unilateral root claudication were analyzed in a double-blind comparison of salmon calcitonin (SCT) and placebo, receiving either 100 IU SCT or 1 ml saline four times a week for 8 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.